816-43-3

Basic information

• Product Name: LITHIUM DIETHYLAMIDE
• Synonyms: LITHIUM DIETHYLAMIDE;Lithiumdiethylamideoffwhitepowder;LITHIUM DIETHYLAMIDE, 95+%;Ethanamine, N-ethyl-, lithium salt;(Diethylamino)lithium;Diethylaminolithium;Diethyllithioamine;N-Lithiodiethylamine
• CAS NO: 816-43-3
• Molecular Formula: C₄H₁₀LiN
• Molecular Weight: 79.07
• EINECS: 212-433-4
• Product Categories: Chemical Synthesis;Organic Bases;Synthetic Reagents;metal amide
• Mol File: 816-43-3.mol

Chemical Properties

• Appearance: off-white to light-orange/solid
• Sensitive: moisture sensitive
• CAS DataBase Reference: LITHIUM DIETHYLAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: LITHIUM DIETHYLAMIDE(816-43-3)
• EPA Substance Registry System: LITHIUM DIETHYLAMIDE(816-43-3)

Safety Data

• Hazard Codes: F,C
• Statements: 17-34
• Safety Statements: 16-26-27-36/37/39-45
• RIDADR: UN 3393 4.2/PG 1
• WGK Germany: 3
• HazardClass: 4.2
• PackingGroup: I
• Hazardous Substances Data: 816-43-3(Hazardous Substances Data)

Usage

Chemical Description

Lithium diethylamide and n-butyllithium are strong bases that are used in organic synthesis.

InChI:InChI=1/C4H11N.Li/c1-3-5-4-2;/h5H,3-4H2,1-2H3;/q;+1

Upstream product

• 881-42-5 diphenylmethyllithium 
• 109-89-7 diethylamine 
• 733-90-4 trityllithium 
• 109-72-8 n-butyllithium 
• 108-18-9 diisopropylamine 

Downstream Products

• 100-38-9 2-(diethylamine)ethanethiol 
• 6292-07-5 diethyl-(2-ethyl-hexyl)-amine 
• 91-66-7 N,N-diethylaniline 
• 15144-80-6 N,N-diethyl-4-methoxyaniline 
• 92-18-2 N,N-diethyl-3-methoxyaniline 
• 5554-72-3 2-Diaethylamino-1,1-diphenyl-aethanol-(1) 
• 533-32-4 N,N-diethyl-3-methylbutanamide 
• 108-83-8 diisobutyl ketone 
• 100-66-3 methoxybenzene 
• 91-68-9 3-diethylaminophenol 
• 91-20-3 naphthalene 
• 84-95-7 N,N-diethyl-1-naphthylamine 
• 13672-17-8 N,N-diethylnaphthalen-2-amine 
• 34874-64-1 N,N-diethyl-N',N'-dimethyl-m-phenylenediamine 

Relevant articles and documents

Guanidinatoaluminum complexes: Synthesis, crystal structures and reactivities

Treatment of diethylaminolithium with carbodiimide (CyNCNCy or CyNCNC6H5) and dimethylaluminium chloride (AlMe2Cl) in a molar ratio of 1:1:1 afforded two kinds of guanidinatoaluminum complexes, [{(Et2N)C(NR1)(NR2)}AlMe2] (R1, R2 = Cy (1); R1 = Cy, R2 = C6H5 (2)) and [{(Et2N)C(NCy)(NC6H5)}2AlMe] (3). The reactivities of the mononuclear guanidinatoaluminum complexes (1 and 2) with O2 or carbodiimide were studied. The complexes of [{(Et2N)C(NCy)2}AlMe(μ-OMe)]2 (4) and [{N(C6H5)C(NCy)N(C6H5)C(NEt2)N(Cy)}AlMe2] (5) were produced by introducing dry oxygen or carbodiimide (CyNCNC6H5) slowly into the solution of the mononuclear guanidinatoaluminum complex (1 or 2). Meanwhile, the addition of O2 or carbodiimide (ArNCNC6H5, Ar = 2,6-Me2C6H3) to the reaction solution of diethylaminolithium with ArNCNC6H5 and AlMe2Cl in a molar ratio of 1:1:1 yielded [(Et2N)C(NC6H5)(NAr)AlMe(μ-OMe)]2 (6) and [{N(C6H5)C(NAr)N(C6H5)C(NEt2)N(Ar)}AlMe2] (7). In addition, a one-pot reaction of diethylaminolithium with CyNCNCy and AlMe2Cl in a molar ratio of 1:1:1 in the presence of H2O produced a tetranuclear guanidinatoaluminum complex, (8), which was also prepared by treatment of complex 1 with equivalent AlMe3 and H2O in 35% yield. All complexes 1-8 were characterized by 1H, 13C NMR spectroscopy and single crystal X-ray diffraction analysis.

Synthesis of ent-kaurane and beyerane diterpenoids by controlled fragmentations of overbred intermediates

Efficient access to minimally oxidized members of the ent-kaurane and beyerane class of terpenes has been achieved by using a polyene cyclization precursor designed to directly yield oxidation at the axial C19-methyl group. Construction of the [3.2.1]bicyclic system found in the ent-kaurane skeleton was realized with two overbred intermediates. Wagner-Meerwein rearrangement of the [3.2.1]bicyclic system yields the beyerane skeleton of isosteviol. Copyright

IMIDE COMPLEX, METHOD FOR PRODUCING THE SAME, METAL-CONTAINING THIN FILM AND METHOD FOR PRODUCING THE SAME

Objects of the present invention are to provide a novel niobium or tantalum complex having good vapor pressure and becoming a raw material for producing a niobium- or tantalum-containing thin film by a method such as CVD method, ALD method or the like, a method for producing the same, a metal-containing thin film using the same, and a method for producing the same. The present invention relates to producing an imide complex represented by the general formula (1) by, for example, the reaction between M1(NR1)X3(L)r (2) and an alkali metal alkoxide (3): (wherein M1 represents niobium atom or tantalum atom, R1 represents an alkyl group having from 1 to 12 carbon atoms, R2 represents an alkyl group having from 2 to 13 carbon atoms, X represents halogen atom, r is 1 when L is 1,2-dimethoxyethane ligand, r is 2 when L is pyridine ligand, and M2 represents an alkali metal), and producing a niobium- or tantalum-containing thin film by using the imide complex (1) as a raw material.

Oxidative amination of cuprated pyrimidine and purine derivatives

Using regioselective cuprations (via magnesiations), various primary, secondary and tertiary aminated pyrimidine and purine derivatives were prepared by the oxidative coupling of lithium amidocuprates using chloranil. DNA and RNA units such as aminated uracil or thymine, and adenine, as well as a CDK inhibitor, purvalanol A, were all obtained under mild conditions and satisfactory yields.

PROCESS FOE SYNTHESIZING 2-PHENYL-1H-PHENANTRHO[9,10-D]IMIDAZOLE DERIVATIVE

The present invention describes an efficient and economical process for the preparation of a 2,3-disubstituted 2-phenyl-1h-phenantrho[9,10-d]imidazole derivative that is useful for the large scale production of material for preclinical and clinical use. The process of the present invention represents a convergent approach to generate the 2,3-disubstituted 2-phenyl-1h-phenantrho[9,10-d]imidazole derivative in high overall yield. The compound made by the process of the invention is an inhibitor of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and is therefore useful to treat pain and/or inflammation from a variety of diseases or conditions such as osteoarthritis, rheumatoid arthritis and acute or chronic pain

2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS

The invention encompasses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed

METHODS FOR TREATING OR PREVENTING NEOPLASIAS

The present invention is directed to a method for treating or preventing a neoplasia in a human patient in need of such treatment comprising administering to the patient a compound that inhibits microsomal prostaglandin E synthase-1 in an amount that is effective for treating or preventing the neoplasia.

ARALKYL AMINES AS CANNABINOID RECEPTOR MODULATORS

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson’s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, including alcohol and nicotine addiction, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Antiviral agents

The invention provides a compound of formula I: wherein G, R2, and R3 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of treating a herpesvirus infection using such compounds or salts.

Preparation of biphosphine ligands for incorporation into catalytic complexes

This invention relates to processes for making phosphorus compounds R2P—X—PR2, R2P—M, R2P—L and R3P, and the novel cation R2P+(L)—X—P+(L)R2, where R represents an optionally substituted hydrocarbyl group, X represents a bridging group, L represents a leaving group and M represents an alkali metal atom. The invention relates further to a process for making a compound R2P—L from a compound R—H via a new process for making the compound R—Li followed by its reaction with a compound Hal2P—L. The compound R2P—X—PR2is a ligand suitable for making catalysts for copolymerizing carbon monoxide and a olefinically unsaturated compound.